Results 101 to 110 of about 22,239 (295)

Purification and Identification of Novel Dipeptidyl Peptidase IV Inhibitory Peptides Derived from Bighead Carp (Hypophthalmichthys nobilis)

Foods
Dipeptidyl peptidase IV (DPP-IV) inhibitors are widely used in treating type 2 diabetes due to their ability to lower blood glucose levels. However, synthetic versions often lead to gastrointestinal side effects.
Hanzhi Zheng, Leyan Zhao, Yushuo Xie, Yuqing Tan   +3 more
doaj   +1 more source

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink, Mark van Avesaat, Simon W. Nienhuijs, Arnold Stronkhorst, Ad A. M. Masclee   +4 more
wiley   +1 more source

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Baptist GallwitzDept Medicine IV, Tübingen University, Otfried-Müller-Str, 10, 72076 Tübingen, GermanyAbstract: Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration
Gallwitz B
doaj   +2 more sources

The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

Clinical Pharmacology: Advances and Applications, 2016
Melanie Davies,1,2 Sudesna Chatterjee,1,2 Kamlesh Khunti1,2 1Diabetes Research Centre, University of Leicester, 2Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK Abstract: Worldwide, an estimated 200 million people ...
Davies M, Chatterjee S, Khunti K
doaj  

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]

, 2018
Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel, Buzzetti, Raffaella, Chevalier, Soazig, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Pettus, Jeremy Hodson, Stella, Peter, Yale, Jean-François   +7 more
core   +4 more sources

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome. [PDF]

Int J Appl Basic Med Res, 2023
Suman RK, Borde MK, Mohanty IR, Singh HK.   +3 more
europepmc   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, EarlyView.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes [PDF]

, 2017
AIMS: The inability of kidneys to prevent urinary protein leakage represents the earliest sign of renal damage in diabetic kidney disease (DKD). Recent data suggest the possible nephroprotective role of the dipeptidyl peptidase-4 (DPP-4) inhibitors ...
Blaslov, Kristina, Duvnjak, Lea, Nikolac Perković, Matea   +2 more
core   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, EarlyView.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents. [PDF]

Molecules, 2022
Mohammad BD, Baig MS, Bhandari N, Siddiqui FA, Khan SL, Ahmad Z, Khan FS, Tagde P, Jeandet P.   +8 more
europepmc   +1 more source